Eli Lilly and Insilico Medicine secure $2.75B deal for AI drug development

Eli Lilly has signed a global licensing and research deal with Insilico Medicine valued at up to $2.75 billion, including $115 million upfront and the rest tied to milestones and royalties. The agreement gives Lilly exclusive worldwide rights to develop and commercialize several preclinical oral therapies reportedly including an oral GLP‑1 candidate while both companies jointly run discovery programs using Insilico’s generative‑AI platform alongside Lilly’s development engine.

Insilico Medicine, a Hong Kong-listed outlier in biotech, has generated at least 28 drug candidates with genAI, nearly half already in clinical trials. Its lead asset, rentosertib, is the first investigational drug in history where both the target (TNIK) and the molecule were discovered entirely by AI, moving from target identification to preclinical candidate in 18 months with only 60–200 molecules synthesized-far above traditional hit rates.

For Lilly, the deal is a strategic hedge as its tirzepatide franchise eventually faces generic pressure to accelerate next‑generation molecules. Across the biotech industry, more than 170 AI‑originated programs are now in clinical development, with Phase 1 success rates far exceeding historical norms. With traditional drug development timelines and costs increasingly unsustainable, Lilly’s $2.75 billion bet signals a structural shift-and raises the question of whether other major pharma companies waited too long to make a similar move.

Read more via the link